You are here
Pharmacokinetic Profile of Trogarzo™ Presented at IDWeek
MONTREAL, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that pharmacokinetic data from the pivotal phase III clinical trial for Trogarzo™ (ibalizumab-uiyk) injection will be presented tomorrow at IDWeek™ in San Francisco.
Data to be presented conclude that the FDA-approved dosing regimen of 2,000 mg loading dose followed by an 800 mg maintenance dose every two weeks is enough to support high levels of CD4 receptor occupancy and drug concentration above therapeutic level.
The data is derived from the pivotal TMB-301 study, an open-label 24-week, phase III clinical trial conducted in 40 heavily-treatment experienced patients with multidrug resistant HIV-1. Results from the TMB-301 clinical trial were published in the August 16, 2018 edition of the New England Journal of Medicine.
“IDWeek is one of the largest conferences in the field of infectious diseases and is attended by some of the world’s key opinion leaders in the field of HIV. Being able to present additional evidence about the efficacy of Trogarzo™ at such an important venue is key towards developing the full potential of this crucial tool in the fight against HIV,” said Luc Tanguay, President and CEO, Theratechnologies Inc.
About TrogarzoTM (ibalizumab-uiyk) injection
Trogarzo™ is a CD4-directed post-attachment HIV-1 inhibitor.
Trogarzo™, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.
Before you receive Trogarzo™, tell your healthcare provider if you are pregnant or plan to become pregnant as it is not known if Trogarzo™ may harm your unborn baby or if you are breastfeeding or plan to breastfeed as it is not known if Trogarzo™ passes into breast milk.
Tell your healthcare provider about all the medicines you take, including all prescription and over-the-counter medicines, vitamins, and herbal supplements.
Changes in your immune system (Immune Reconstitution Inflammatory Syndrome) can happen when you start taking HIV-1 medicines. Your immune system might get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your health care provider right away if you start having new symptoms after starting your HIV-1 medicine.
The most common side effects of Trogarzo™ include: diarrhea, dizziness, nausea and rash.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Trogarzo™. For more information, ask your healthcare provider or pharmacist.
Full prescribing information available at www.trogarzo.com.
Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com.
This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to, the efficacy of Trogarzo™ and its use in assisting patients in need thereof.
Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Theratechnologies’ control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These assumptions include but are not limited to, the following: the efficacy observed during the pivotal phase III clinical trial for Trogarzo™ will be the same for all patients and physicians will acknowledge and prescribe Trogarzo™ to patients in need thereof.
These risks and uncertainties include, but are not limited to, the risk that the efficacy of TrogarzoTM differs from one patient to the other and that physicians are reluctant to prescribe Trogarzo™.
We refer potential investors to the “Risk Factors” section of our Annual Information Form dated February 6, 2018 available on SEDAR at www.sedar.com for additional risks and uncertainties about Theratechnologies, its business and products. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.
Vice President, Communications and Corporate Affairs
Tel.: (514) 336-7800, ext. 236